<DOC>
	<DOCNO>NCT01510132</DOCNO>
	<brief_summary>The purpose multi-center , open label , single arm , post-marketing surveillance study assess safety Travacom patient open-angle glaucoma ocular hypertension insufficiently responsive beta-blockers , prostaglandin , intraocular pressure-lowering ( IOP ) medication use Travacom consider appropriate .</brief_summary>
	<brief_title>Travacom Post Marketing Surveillance Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>18 year age old . Openangle glaucoma ocular hypertension insufficiently responsive betablockers , prostaglandin , intraocular pressurelowering ( IOP ) agent use Travacom consider appropriate . Discontinued use ocular hypotensive medication prior receive study medication entire course study . Mean IOP great 36 mmHG either eye . Read , sign , date ( legal representative ) Informed Consent prior start studyrelated procedure . Other protocoldefined inclusion criterion may apply . Women childbearing potential ( postmenopausal least one year surgically sterile ) currently pregnant , positive result urine pregnancy test Screening , intend become pregnant study period , breastfeeding , agree use adequate birth control method prevent pregnancy throughout study . Chronic , recurrent , severe inflammatory eye disease , scleritis , uveitis , herpes keratitis . History clinically significant progressive retinal disease . Best correct visual acuity ( BCVA ) score bad 20/80 Snellen . Bronchial asthma related history would preclude safe administration topical betablocker . Severe , unstable , uncontrolled cardiovascular , hepatic , renal disease related history would preclude safe administration topical betaadrenergic block agent . History spontaneous current hypoglycemia uncontrolled diabetes . Known medical allergy , hypersensitivity , poor tolerance component Travacom deem clinically significant opinion Principal Investigator . Use additional topical system ocular hypotensive medication study . Participation investigational study within 30 day prior Screening visit . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>OAG</keyword>
	<keyword>OHT</keyword>
</DOC>